MGTX
MeiraGTx Holdings plc is a clinical-stage genetic medicines company developing gene therapy programs for radiation-induced xerostomia, Parkinson's disease, and AIPL1-associated retinal dystrophy using targeted local delivery of viral vectors to the eye, salivary gland, and central nervous system. The company is also advancing a proprietary riboswitch platform that enables oral small molecule control of in vivo biologic production, including GLP-1, GIP, and other metabolic peptides, alongside cell therapy candidates for oncology and autoimmune diseases. MeiraGTx operates GMP-certified viral vector manufacturing facilities in London and Shannon with end-to-end internal production capabilities including plasmid manufacturing and quality control testing.